ES2019728A6 - Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma. - Google Patents

Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma.

Info

Publication number
ES2019728A6
ES2019728A6 ES8903606A ES8903606A ES2019728A6 ES 2019728 A6 ES2019728 A6 ES 2019728A6 ES 8903606 A ES8903606 A ES 8903606A ES 8903606 A ES8903606 A ES 8903606A ES 2019728 A6 ES2019728 A6 ES 2019728A6
Authority
ES
Spain
Prior art keywords
cell
vaccine
produced
antigens
msm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES8903606A
Other languages
English (en)
Spanish (es)
Inventor
Malcolm S Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California
Original Assignee
University of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California filed Critical University of Southern California
Publication of ES2019728A6 publication Critical patent/ES2019728A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES8903606A 1988-09-23 1989-09-22 Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma. Expired - Lifetime ES2019728A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24854388A 1988-09-23 1988-09-23

Publications (1)

Publication Number Publication Date
ES2019728A6 true ES2019728A6 (es) 1991-07-01

Family

ID=22939592

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8903606A Expired - Lifetime ES2019728A6 (es) 1988-09-23 1989-09-22 Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma.

Country Status (4)

Country Link
JP (1) JPH04501663A (ja)
AU (1) AU4338189A (ja)
ES (1) ES2019728A6 (ja)
WO (1) WO1990003183A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620350D0 (en) 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
ATE407695T1 (de) * 1999-02-09 2008-09-15 Riken Tumorimpfstoff
AU4935700A (en) * 1999-05-21 2000-12-12 Onyvax Limited New vaccine formulations-3
US8409564B2 (en) 1999-10-05 2013-04-02 Universite De Montreal Rhodamine derivatives for photodynamic diagnosis and treatment
RU2152800C1 (ru) * 1999-12-08 2000-07-20 Зыбин Дмитрий Владимирович Способ культивирования и модификации гетерогенных клеток млекопитающих
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
EP1447092A4 (en) * 2001-09-28 2007-07-11 Haruo Sugiyama METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
AU2004294243B2 (en) * 2003-12-05 2011-02-17 Hopital Maisonneuve-Rosemont Immunologic compounds for prevention, protection, prophylaxis or treatment of immunological disorders, infections and cancer
GB0601598D0 (en) * 2006-01-26 2006-03-08 Stathopoulos Apostolos Method
RU2392316C1 (ru) * 2008-12-26 2010-06-20 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Ksen, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
AU2012257377B2 (en) 2011-05-17 2017-09-07 Hadasit Medical Research Services And Development Ltd. Allogeneic tumor cell vaccination
PT2941233T (pt) * 2013-01-07 2020-11-13 Univ Pennsylvania Composições e métodos para tratar linfoma cutâneo de células t

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4505900A (en) * 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant

Also Published As

Publication number Publication date
AU4338189A (en) 1990-04-18
JPH04501663A (ja) 1992-03-26
WO1990003183A1 (en) 1990-04-05

Similar Documents

Publication Publication Date Title
Chou et al. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.
CA2204666A1 (en) Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
UA40597C2 (uk) Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
TR200100936T2 (tr) Terapötik aşılama
Hanna Jr et al. Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. II. Comparative effects of vaccinia virus, oxazolone, and turpentine
EP0752870B1 (en) Use of mycobacterium for the treatment of tumours
MXPA03003638A (es) Inmunoterapia con vacuna para pacientes inmunosuprimidos.
MXPA04003864A (es) Inmunoterapia para revertir la supresion inmune.
CN101282742A (zh) 脂质体在含连续疏水相的载体中作为癌症治疗媒介物的应用
AR068984A1 (es) Proceso para la obtencion de celulas presentadoras de antigenos activados, utiles en las terapias contra el cancer y enfermedades relacionadas del sistema inmunologico
Eilber et al. Immunotherapy experiments with a methylcholanthrene-induced guinea pig liposarcoma
AU7767000A (en) Archaeosomes as immunomodulating carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses and protect the vaccinated host against intracellular pathogens and cancer
Deckers et al. The adoptive transfer of concomitant immunity to murine tumor isografts with spleen cells from tumor-bearing animals
KOHWI et al. Antitumor and immunological adjuvant effect of Bifidobacterium infantis in mice
WO1990003183A1 (en) Immunotherapy vaccine for melanoma tumors
Conforti et al. Update on active specific immunotherapy with melanoma vaccines
CA2330313A1 (en) Immunization against and treatment for infection by h.pylori
WO2001056601A3 (en) Low dose haptenized tumor cell and tumor cell extract immunotherapy
US6090385A (en) Method of treating cancer
WO1995032286A3 (en) Immunogenic carcinoembryonic antigen and methods of use and production
US6056964A (en) Immunotherapeutic agent and its use
Weiner Immunostimulatory DNA sequences and cancer therapy
Braun et al. Generation of Anti-MOPC-315 Cytotoxicity in Uneducated or in Vitro Educated Spleen Cells from Normal or MOPC-315 Tumor-bearing Mice Pretreated in Vivo with Bacillus Calmette-Guérin
Sethi et al. Brief communication: Protection of mice from malignant tumor implants by enucleated tumor cells
EP1240309A2 (en) Immature autologous clinical grade dendritic cells intended for vaccination of cancer patients

Legal Events

Date Code Title Description
SA6 Expiration date (snapshot 920101)

Free format text: 2009-09-22